Aprepitant Patent Expiration
Aprepitant is Used for preventing and treating nausea and vomiting associated with chemotherapy, postoperative nausea and vomiting, and emesis induced by cancer chemotherapeutic agents. It was first introduced by Merck And Co Inc
Aprepitant Patents
Given below is the list of patents protecting Aprepitant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aponvie | US10500208 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US10953018 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11878074 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12290520 | Methods of use of emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9561229 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9808465 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974793 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974794 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10500208 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10953018 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12290520 | Methods of use of emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9561229 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9808465 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974793 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974794 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Emend | US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | Sep 26, 2027 | Merck |
| Emend | US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | Sep 26, 2027 | Msd Merck Co |
| Emend | US6096742 | Polymorphic form of a tachykinin receptor antagonist |
Jul 01, 2018
(Expired) | Merck |
| Emend | US6096742 | Polymorphic form of a tachykinin receptor antagonist |
Jul 01, 2018
(Expired) | Msd Merck Co |
| Emend | US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr 17, 2015
(Expired) | Merck |
| Emend | US5538982 | Medical use for tachykinin antagonists |
Jul 23, 2013
(Expired) | Merck |
| Emend | US7214692 | Medical use for tachykinin antagonists |
Sep 18, 2012
(Expired) | Merck |
Aprepitant's Family Patents
Explore Our Curated Drug Screens
Aprepitant Generic API Manufacturers
Several generic applications have been filed for Aprepitant. The first generic version for Aprepitant was by Sandoz Inc and was approved on Sep 24, 2012. And the latest generic version is by Torrent Pharma Inc and was approved on Oct 21, 2020.
Given below is the list of companies who have filed for Aprepitant generic, along with the locations of their manufacturing plants worldwide.
1. GLENMARK SPECLT
Glenmark Specialty Sa has filed for 3 different strengths of generic version for Aprepitant. Given below are the details of the strengths of this generic introduced by Glenmark Speclt.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 80MG | capsule | Prescription | ORAL | AB | Oct 12, 2017 |
| 40MG | capsule | Prescription | ORAL | AB | Oct 12, 2017 |
| 125MG | capsule | Prescription | ORAL | AB | Oct 12, 2017 |
2. SANDOZ
Sandoz Inc has filed for 3 different strengths of generic version for Aprepitant. Given below are the details of the strengths of this generic introduced by Sandoz.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG | capsule | Prescription | ORAL | AB | Sep 24, 2012 |
| 80MG | capsule | Prescription | ORAL | AB | Sep 24, 2012 |
| 125MG | capsule | Prescription | ORAL | AB | Sep 24, 2012 |
Manufacturing Plant Locations New
Sandoz's manufacturing plants are situated in 4 countries - Austria, United States, Spain, India. Given below are the details of these plant locations as well as the firm names of Sandoz as present at those locations.
| Country | City | Firm Name | ||||
|---|---|---|---|---|---|---|
| Austria |
| |||||
| United States |
| |||||
| Spain |
| |||||
| India |
| |||||
3. TORRENT
Torrent Pharma Inc has filed for 3 different strengths of generic version for Aprepitant. Given below are the details of the strengths of this generic introduced by Torrent.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 40MG | capsule | Prescription | ORAL | AB | Oct 21, 2020 |
| 80MG | capsule | Prescription | ORAL | AB | Oct 21, 2020 |
| 125MG | capsule | Prescription | ORAL | AB | Oct 21, 2020 |
Manufacturing Plant Locations New
Torrent's manufacturing plants are situated in 2 countries - India, United States. Given below are the details of these plant locations as well as the firm names of Torrent as present at those locations.
| Country | City | Firm Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| India |
| |||||||||||
| United States |
| |||||||||||